UsAgainstAlzheimer’s Applauds Passage of $350 Million Increase for Alzheimer’s Research

UsA2 Urges President to Sign Federal Spending Bill Allocating $2.8 billion for Alzheimer’s Research in FY2020

Washington, D.C. (December 19, 2019) UsAgainstAlzheimer’s today issued the following statement from George Vradenburg, chairman and co-founder, following the Senate vote to approve the 2020 appropriations bill containing a $350 million increase, to $2.8 billion, for Alzheimer’s and dementia research at the National Institutes of Health. The legislation was approved by the House on Tuesday and will now go to President Trump for his signature.

“With this increase, Congress has demonstrated a serious commitment to funding Alzheimer’s research – and it’s time for President Trump to do the same. This $350 million increase in research funding tells the 5.8 million Americans living with Alzheimer’s and their 16 million caregivers that our nation is committed to stopping this disease.

“The growing federal investment in Alzheimer’s research is paying off. Two new drug therapies are expected to seek regulatory approval in 2020 and scientists have made progress in understanding the causes of this disease, which is critical for the breakthroughs in treatment and prevention that patients, caregivers and families need. 

"We urge President Trump to show global leadership on this issue and sign this legislation to fund research critical to stopping Alzheimer’s.”


About UsAgainstAlzheimer’s (UsA2)

UsAgainstAlzheimer’s (UsA2) is a disruptive advocacy and research-focused organization that is pressing for greater resources and speed in the development of and access to effective interventions for the prevention and treatment of Alzheimer’s disease. UsA2’s transformative programming is laser-focused on fostering brain health across the lifespan and assuring that the voice and insights of those affected by the disease are heard, including, importantly, communities of color and low income.